Published in final edited form as:

J Med Chem. 2008 August 28; 51(16): 5118–5120. doi:10.1021/jm800496s.

Reductive Heme-Dependent Activation of the N-Oxide Prodrug AQ4N by Nitric Oxide Synthase

Clinton R. Nishida and Paul R. Ortiz de Montellano*

Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, CA 94158-2517

Abstract

Anaerobic reduction of anticancer prodrugs is a promising route to achieve targeting and selectivity in anticancer drug design. Most reductive prodrug activations involve simple electron transfer from a flavoprotein and are not amenable to specific targeting. Here we report that the N-oxide AQ4N is reduced by a nitric oxide synthase. This reduction involves interaction with the heme iron atom in the active site and is thus subject to specific protein constraints.

One of the crucial problems in cancer chemotherapy is specific targeting of the therapeutic agent to tumor rather than normal cells, as anticancer agents generally interfere equally well with the intended target in both types of cells. One of the features of cancer cells in solid tumors that has been exploited for this purpose is the relatively low oxygen tension inside the tumor due to poor vascularization of the tissue.¹ This hypoxia enables the reductive activation of anticancer prodrugs that cannot be similarly activated in normoxic tissues due to competing oxidative pathways. Among the drugs and potential anticancer agents that are activated in this manner are tirapazamine,² mitomycin,³ **1** (NLCQ-1),^{4,a} **2** (KS119),⁵ and **3** (AQ4N).⁶

The reductive activation of most prodrugs in hypoxic tissues is generally mediated by electron transfer from the flavoprotein NADPH-cytochrome P450 reductase.^{4,7} However, it has more recently been shown that the flavoprotein domain of nitric oxide synthases (NOS) lacking the heme domain can also provide electrons for activation of some of these agents, including tirapazamine and doxorubicin.⁸ The NOS are of interest in this context because their concentration is often elevated in tumor tissues.⁹ They may therefore make a significant contribution to the activation of prodrugs in hypoxic tumor cells and could in principle be exploited as specific targets for such activation. This would be desirable as it would impose an additional constraint favoring tumor-specific activation of the agent. Unfortunately, electron transfer from both the NADPH-cytochrome P450 reductase and the NOS flavoprotein domain is relatively non-specific, so that targeting of prodrugs for specific activation by flavoprotein electron donors may not be feasible.

3 is a *bis*-N-oxide anticancer prodrug that, when reduced to the *bis*-amine, is a potent inhibitor of topoisomerase II.¹⁰ The prodrug itself has virtually no activity against this target enzyme

*To whom correspondence should be addressed. Phone: 415-476-2903. Fax: 415-502-4728. E-mail: ortiz@cgl.ucsf.edu.

SUPPORTING INFORMATION AVAILABLE: Experimental methods and azole inhibition of **3** reduction. This material is available free of charge via the Internet at <http://pubs.acs.org>.

^aAbbreviations: AQ4N, 1,4-bis- {[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; AQ4M, 1- {[2-(dimethylamino-N-oxide)ethyl]amino}-4- {[2 (dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione, AQ4, 1,4-bis- {[2-(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; CYP, cytochrome P450; HPLC, high-performance liquid chromatography; KS119, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine; iNOS, inducible isoform of nitric oxide synthase (NOS-2); nNOS, neuronal isoform of NOS (NOS-1); NADPH, nicotinamide adenine dinucleotide phosphate (reduced form); NLCQ-1, 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride.

and, in the absence of reduction, is relatively nontoxic. **3** differs from the other agents because it is not activated by simple electron transfer from P450 reductase. However, it is activated by cytochrome P450 enzymes, with the highest activity reported for human CYP3A4.¹¹ It is likely that this involves direct interaction of **3** with the active site iron atom, although the only actual evidence for this is that carbon monoxide inhibits the bioactivation reaction.¹² In view of the elevation of the NOS enzymes in tumor cells, we have investigated whether the nitric oxide synthases can activate **3**, have examined the nature of the reaction, and have compared the activity of human hepatic inducible nitric oxide synthase (iNOS) with that of CYP3A4. The results open the exciting possibility that anaerobically activated prodrugs can be selectively targeted for activation by NOS enzymes.

Incubation of iNOS and NADPH with **3** under anaerobic conditions (glove box) led to sequential reduction of **3** to the mono-N-oxide **4** (AQ4M) and then to the active drug **5** (AQ4) (Figure 1). The products were identified by HPLC comparison with authentic standards. A time course of the reaction showed that **3** was first converted to **4**, which accumulated in the medium and was subsequently converted to **5** (Figure 2). No product formation was observed in the absence of either NADPH or NOS, under aerobic conditions, or if the NOS enzyme was replaced by purified NADPH-cytochrome P450 reductase. Beyond their sequence homology, CYP reductase and the iNOS reductase domain are comparable in terms of activities with regard to reduction of small molecule electron acceptors such as ferricyanide and of protein electron acceptors such as cytochrome c. Thus, these results clearly show that the reaction requires the NOS heme domain and is not simply the result of electron transfer from the flavoprotein domain.

In order to evaluate the conditions required for **3** reduction, we have determined the K_m value for the iNOS reaction. The K_m for the conversion of **3** to **4** is $130 \pm 30 \mu\text{M}$, but the K_m for the conversion of **4** to **5** could not be determined. A plot of product formation versus **4** (substrate) concentration did not reach a plateau at nominal concentrations below $500 \mu\text{M}$. Although **3** has two N-oxide moieties, it bears no net formal charge and is much less polar than **4**, which has a trialkylamine substituent that is protonated at pH 7. It is possible that only the unprotonated **3** is bound in the NOS active site, and thus that only a small fraction of the added **4** is available to the enzyme. Nevertheless, as the time-course studies demonstrate, the NOS enzymes can fully reduce **3** to the anticancer-active agent **5**.

We have also determined the oxygen sensitivity of the reductive reaction by measuring the rate of **4** or **5** formation as a function of increasing oxygen concentration (Figure 3). As shown in the figure, the highest product formation is observed under fully anaerobic conditions, but half-maximal product formation occurs at 4–5% oxygen.

A comparison of the activities of iNOS and CYP3A4 is informative, as it shows that iNOS, with a rate of $\sim 5 \text{ min}^{-1}$, has a ten-fold higher activity than CYP3A4, for which the activity is $\sim 0.5 \text{ min}^{-1}$ both in assays with the reconstituted purified enzyme and CYP3A4 insect cell microsomes (BD Biosciences). Comparison with other NOS isoforms demonstrates a correlation between native NOS activity and reduction of **3**. The neuronal isoform (nNOS) exhibited an observed activity of $\sim 2 \text{ min}^{-1}$, and the level of endothelial NOS (eNOS) activity also closely mirrored the lower native activity observed for eNOS nitric oxide production from arginine compared to those of iNOS and nNOS; that is, turnover of **3** by eNOS was approximately 10-fold less than by iNOS, 0.5 min^{-1} .

It is of note that heme and NADPH alone can reduce **3** under anaerobic conditions, including under quench conditions. However, since the background reaction of iNOS under quench conditions was negligible, the observed products were formed by iNOS rather than free heme.

Arginine at 1 mM (apparent K_m for iNOS of $2.8 \mu\text{M}^{14}$) did not inhibit anaerobic reduction of **3**. Although the K_m for **3** is fairly high at $130 \mu\text{M}$, reduction of an N-oxide via heme coordination under anaerobic conditions may be non-competitive with arginine binding. In contrast, evidence in support of the reaction of **3** with the heme iron is provided by the 50% inhibition of **3** reduction to **5** by either $50 \mu\text{M}$ econazole or clotrimazole. Both of these azole agents are known to coordinate to the NOS heme iron atom.

If reduction of **3** involves direct oxygen transfer from the N-oxide to the heme of iNOS, as indicated by our results, the N-oxide would be expected to coordinate to the heme iron atom at some point in the reductive mechanism. However, we have not detected direct heme coordination by UV-vis spectroscopy in a titration of ferric iNOS with up to $450 \mu\text{M}$ **3** or **4**. It is therefore likely that coordination only occurs with the ferrous iron, to which the oxygen atom is then immediately transferred (Figure 4). The resulting hypervalent iron would then be reduced by further electron transfer from the NOS reductase domain.

Targeting prodrugs such as **3** for reductive activation in relatively anaerobic tissues by NOS enzymes may provide a new dimension that is relevant to, for example, agents directed at the treatment of solid tumors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank John Curd of Novacea, Inc., for suggesting this problem and for stimulating discussions and Al Lalani of Novacea for **3** and samples of its metabolites. This research was supported by National Institutes of Health grant GM25515.

References

1. (a) Brown MJ. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. *Molec Med Today* 2000;6:157–162. [PubMed: 10740254] (b) Lee K, Roth RA, LaPres JJ. Hypoxia, drug therapy and toxicity. *Pharmacol Therap* 2007;113:229–246. [PubMed: 17046066]
2. Brown MJ. The hypoxic cell: A target for selective cancer therapy --Eighteenth Bruce F. Cain Memorial Award lecture. *Cancer Res* 1999;59:5863–5870. [PubMed: 10606224]
3. Tomasz M. Mitomycin C: Small, fast and deadly (but very selective). *Chem Biol* 1995;2:575–579. [PubMed: 9383461]
4. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreductive drug. *Clin Cancer Res* 2003;9:5714–5720. [PubMed: 14654556]
5. Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: An anticancer agent targeting hypoxic cells. *Proc Nat Acad Sci USA* 2005;102:9282–9287. [PubMed: 15964988]
6. (a) Lalani AS, Alters SE, Wong A, Albertella MR, Cleland JL, Henner WD. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. *Clin Cancer Res* 2007;13:2216–2225. [PubMed: 17404106] (b) Patterson LH. Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. *Drug Metab Rev* 2002;34:581–592. [PubMed: 12214668]
7. (a) Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome. P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. *Biochem Pharmacol* 1992;44:251–259. [PubMed: 1642640] (b) Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ, Rockwell S. Mitomycin C: A prototype bioreductive agent. *Oncol Res* 1994;6:501–508. [PubMed: 7620218]

8. (a) Garner AP, Paine MJI, Rodriguez-Crespo I, Chinje EC, Ortiz de Montellano PR, Stratford IJ, Tew DG, Wolf CR. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. *Cancer Res* 1999;59:1929–1934. [PubMed: 10213502] (b) Jiang H-B, Ichikawa M, Furukawa A, Tomita S, Ichikawa Y. Reductive activation of mitomycin C by neuronal nitric oxide synthase. *Biochem Pharmacol* 2000;60:571–579. [PubMed: 10874132] (c) Kumagai Y, Nakajima H, Midorikawa K, Homma-Takeda S, Shimojo N. Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: Nitric oxide synthase as a quinone reductase. *Chem Res Toxicol* 1998;11:608–613. [PubMed: 9625728] (d) Matsuda H, Kimura S, Iyanagi T. One-electron reduction of quinones by the neuronal nitric-oxide synthase reductase domain. *Biochim Biophys Acta* 2000;1459:106–116. [PubMed: 10924903]
9. (a) Atik E, Ergin M, Erdogan S, Tuncer I. Inducible nitric oxide synthase and apoptosis in human B cell lymphomas. *Molec Cell Biochem* 2006;290:205–209. [PubMed: 16924421] (b) Forstermann U, Gorksy LD, Pollock JS, Ishii K, Schmidt HHHW, Heller M, Murad F. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin. *Molec Pharmacol* 1990;38:7–13. [PubMed: 2370855] (c) Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. *S. Br J Cancer* 1994;70:847–849. [PubMed: 7524602] (d) Werner-Felmayer G, Werner E, Fuchs D, Hausen A, Mayer B, Reibnegger C, Weiss G, Wachter H. Ca^{2+} /calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180. *Biochem J* 1993;289:357–361. [PubMed: 7678733] (e) Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. *Cancer Res* 1995;55:727–730. [PubMed: 7531613] (f) Ambbs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogun-fusika MO, Oser SM, Klwin S, Shields PG, Billiar TR, Harris CC. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. *Cancer Res* 1998;58:334–341. [PubMed: 9443414] (g) Thomsen LL, Sargent JM, Williamson CJH, Elgie AW. Nitric oxide synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. *Biochem Pharmacol* 1998;56:1365–1370. [PubMed: 9825736]
10. (a) Patterson LH, Craven MR, Fisher GR, Teesdale-Spittle P. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. *Oncol Res* 1994;6:533–538. [PubMed: 7620222] (b) Smith PJ, Blunt JN, Desnoyers R, Giles Y, Patterson LH. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. *Cancer Chemother Pharmacol* 1997;39:455–461. [PubMed: 9054961]
11. (a) Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH. Involvement of human hepatic cytochrome P450(CYP's) in the reductive metabolism of AQ4N, a novel anthraquinone based antineoplastic prodrug. *Int J Radiation Oncol Biol Phys* 1998;42:763–767. (b) Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T. Tumour selective drug activation: A GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. *Cancer Gene Therapy* 2006;13:598–605. [PubMed: 16410820]
12. Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Anti-tumour pro-drug development using cytochrome P450 mediated activation. *Anti-Cancer Drug Design* 1999;14:473–486. [PubMed: 10834269]
13. (a) % oxygen based on assumed 35% dissolved O_2 in air-saturated water at 25°C, calculated from gas solubilities^{13b}; Gevantman LH. Lide DR. Solubility of selected gases in water. *CRC Handbook of Chemistry and Physics* (88) CRC Press Boca Raton, FL 2007;88. :8–80–8–83.8–83
14. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD- and FMN-containing flavoprotein. *Proc Natl Acad Sci U S A* 1991;88:7773–7777. [PubMed: 1715579]

Figure 1.

Figure 2.
Time course of 3 reduction by iNOS.

Figure 3. Dependence of **3** and **4** reduction on oxygen concentration. Different ratios of anaerobic and air-saturated solutions were mixed¹³.

Figure 4. Possible mechanism of N-oxide reduction by P450 and NOS involving direct N-oxide coordination to ferrous iron.